Compound 10 demonstrated broader potency against FGFR2/3 mutants acquired after the approved FGFR drug treatments. (IMAGE)

InSilico Medicine

Compound 10 demonstrated broader potency against FGFR2/3 mutants acquired after the approved FGFR drug treatments.

Caption

 It also exhibited robust selectivity, sparing FGFR1/4, and showed minimal off-target effects against a broad panel of kinases. In preclinical models, compound 10 displayed favorable pharmacokinetics, high oral bioavailability, and  induced tumor stasis or regression in gastric cancer mouse models, showing robust antitumor efficacy and pharmacodynamic suppression, highlighting its potential as an effective cancer treatment.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.